ALKS - アルケルメス (Alkermes plc) アルケルメス

 ALKSのチャート


 ALKSの企業情報

symbol ALKS
会社名 Alkermes plc (アルケルメス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アルケルメス(Alkermes plc.)(Alkermes Inc.)は統合されたバイオテクノロジー企業。同社は一般的な慢性疾患の治療のための医薬品の開発、製造と商品化に従事している。同社はアルコール依存症の治療薬「VIVITROL」の開発・製造・商品化、及び統合失調症と双極I型障害の治療薬「RISPERDAL CONSTA」の製造を行っている。同社の薬品パイプラインは中枢神経系(CNS)疾患、報酬障害、中毒、糖尿病と自己免疫疾患などの一般的な慢性疾患の治療のための徐放性注射剤と経口製品を含む。同社はマサチューセッツ州に1カ所の研究施設、オハイオ州に1カ所の商業生産施設を有している。平成23年9月、同社はアイルランドで事業活動を開始した。平成23年9月16日、同社はElan Corporation plc (Elan)の製剤と薬品製造事業ユニットであるエラン医薬品テクノロジーズ(EDT)と合併した。  アルケルメスはアイルランドのバイオ医薬品会社。依存症、統合失調症、うつ病など中枢神経障害の治療用製品の開発と商業化に従事。製品には統合失調症治療薬「リスパダ―ル・コンスタ」、多発性硬化症治療薬「アムピラ」、2型糖尿病治療薬徐放性剤「ビデュリオン」、アルコ―ル依存症治療薬「ビビトロル」などがある。   Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
本社所在地 Connaught House 1 Burlington Road Dublin 02451 IRL
代表者氏名 Richard F. Pops リチャードF.ポップス
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +353 1-772-8000
設立年月日 31959
市場名 NASDAQ National Market System
ipoyear 1991年
従業員数 2000人
url www.alkermes.com
nasdaq_url https://www.nasdaq.com/symbol/alks
adr_tso
EBITDA EBITDA(百万ドル) 7.23400
終値(lastsale) 44.45
時価総額(marketcap) 6903759662.1
時価総額 時価総額(百万ドル) 6709.616
売上高 売上高(百万ドル) 122.547
企業価値(EV) 企業価値(EV)(百万ドル) 6556.5
当期純利益 当期純利益(百万ドル) -119.76600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Alkermes Plc revenues increased 29% to $529.8M. Net loss decreased 15% to $95.2M. Revenues reflect Product sales net increase of 22% to $201.6M Research and development revenue increase from $1.5M to $37.1M. Lower net loss reflects Interest Income increase of 60% to $3.4M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.73 to -$0.61.

 ALKSのテクニカル分析


 ALKSのニュース

   Can you now get a good deal on Alkermes plc’s shares?  2022/09/01 13:48:00 US Post News
In Wednesday’s session, Alkermes plc (NASDAQ:ALKS) marked $23.67 per share, down from $24.25 in the previous session. While Alkermes plc has underperformed by -2.39%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALKS fell by -24.28%, with highs and lows ranging from $33.00 to $21.24, whereas […]
   Investing in Alkermes plc (ALKS) might be a great opportunity, but the stock is a bit undervalued  2022/08/26 14:08:00 US Post News
A share of Alkermes plc (NASDAQ:ALKS) closed at $24.94 per share on Thursday, down from $25.21 day before. While Alkermes plc has underperformed by -1.07%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALKS fell by -18.63%, with highs and lows ranging from $33.00 to $21.24, […]
   Alkermes Earns 2022 Best Place for Working Parents Designation  2022/08/17 14:00:01 CSRwire
For the all the working parents at Alkermes, we recognize that there is no greater responsibility than being present for your family.
   Alkermes initiated at neutral at Piper Sandler as company in transition (NASDAQ:ALKS)  2022/08/16 15:01:09 Seeking Alpha
Piper Sandler has initiated Alkermes (ALKS) with a neutral rating saying that its atypical antipsychotic Lybalvi (olanzapine and samidorphan) will not achieve blockbuster status.The…
   Looking Into Alkermes''s Return On Capital Employed  2022/07/28 15:46:14 Benzinga
According to data from Benzinga Pro, during Q2, Alkermes ''s (NASDAQ: ALKS ) reported sales totaled $276.22 million. Despite a 16.06% increase in earnings, the company posted a loss of $30.14 million. In Q1, Alkermes brought in $278.55 million in sales but lost $35.90 million in earnings. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company … Full story available on Benzinga.com
   Hot Stocks: ALKS rallied on earnings; NCR, COF decline; ARCH sets new high  2022/04/27 22:17:53 Seeking Alpha
ALKS climbed in the wake of its quarterly results. NCR and COF dropped after their respective earnings reports. ARCH added to recent gains to set a fresh high.
   Alkermes plc 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:ALKS)  2022/04/27 17:18:23 Seeking Alpha
The following slide deck was published by Alkermes plc in conjunction with their 2022 Q1 earnings call.
   Bears Are Back On The Defensive As Alkermes plc (ALKS) swung 12.16%  2022/04/27 17:00:00 Marketing Sentinel
Alkermes plc (NASDAQ:ALKS) has a beta value of 0.85 and has seen 1.07 million shares traded in the recent trading session. The company, currently valued at $4.63B, closed the recent trade at $30.44 per share which meant it gained $3.3 on the day or 12.16% during that session. The ALKS stock price is -8.41% off … Bears Are Back On The Defensive As Alkermes plc (ALKS) swung 12.16% Read More »
   Alkermes'' (ALKS) CEO Richard Pops on Q1 2022 Results - Earnings Call Transcript  2022/04/27 16:54:15 Seeking Alpha
Alkermes plc (NASDAQ:NASDAQ:ALKS) Q1 2022 Earnings Conference Call April 27, 2022, 8:00 am ET Company Participants Sandra Coombs - SVP, IR & Corporate Affairs Iain Brown - CFO Todd…
   Why Alkermes Stock Is Jumping Today  2022/04/27 16:37:06 The Motley Fool
The drugmaker beat Wall Street''s expectations with its Q1 results.
   Alkermes'' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer  2022/02/17 16:23:50 Benzinga
Alkermes plc (NASDAQ: ALKS ) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant immunotherapy for advanced renal cell carcinoma (RCC). The data were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium. The presentation includes updated efficacy and safety data from the monotherapy arm of ARTISTRY-1, in which … Full story available on Benzinga.com
   Why Alkermes Stock Blasted 15% Higher Today  2022/02/16 22:26:19 The Motley Fool
The biotech smashed analyst estimates in its final quarter of 2021.
   Alkermes (ALKS) Q4 2021 Earnings Call Transcript  2022/02/16 19:30:30 The Motley Fool
ALKS earnings call for the period ending December 31, 2021.
   Why Are Alkermes Shares Trading Higher Today?  2022/02/16 18:51:57 Benzinga
Alkermes plc''s (NASDAQ: ALKS ) Q4 sales increased 16% Y/Y to $324.5 million , beating the consensus of $308.69 million. Net sales of proprietary products were $178.9 million, compared to $148.96 million in the prior year. Net sales of Vivitrol were $92.04 million, compared to $80.05 million in the prior year. Net sales of Aristada were $78.67 million, compared to $68.91 … Full story available on Benzinga.com
   Alkermes plc. (ALKS) CEO Richard Pops on Q4 2021 Results - Earnings Call Transcript  2022/02/16 18:25:09 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アルケルメス ALKS Alkermes plc)

 twitter  (公式ツイッターやCEOツイッターなど)